Lilly to Acquire Three Vaccine Developers for $4 Billion
Lilly Acquires Three Vaccine Developers, Pushes into Infectious Disease Prevention
Eli Lilly (NYSE: LLY) announced Tuesday it will buy three vaccine developers in deals worth up to nearly $4 billion in combined value, signaling a push by the drugmaker into infectious disease prevention.
The drugmaker, riding a wave of cash from booming demand for its obesity drugs, has been on an acquisition spree as it expands beyond weight loss to other therapeutic areas.
Deal Details
Lilly has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Co. Curevo is developing a vaccine for the prevention of shingles in adults. Curevo shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and milestone payments.
LimmaTech, which is developing vaccines against bacterial pathogens, will be acquired for up to $780 million in cash. The Vaccine Co, developing a vaccine against Epstein-Barr virus, will be acquired for up to $1.55 billion.
Lilly shares were up 1.6% in premarket trading.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…